Overview of 1Q sales trends for Pfizer medicines

A look at the 1st-quarter sales trends for top-selling prescription drugs sold by Pfizer

Associated Press

Here are sales figures for the first quarter for top-selling Pfizer prescription drugs:

PRODUCT NAME MAIN CONDITION/USE 1Q 2011 SALES 1Q 2010 SALES PERCENT CHANGE

Lipitor High cholesterol $1.4 billion $2.4 billion down 42 percent

Lyrica Fibromyalgia/pain $955 million $826 million up 16 percent

Enbrel (outside U.S.) Rheumatoid arthritis $899 million $870 million up 3 percent

Prevnar 7/Prevnar 13 Pneumococcal vaccine $1.08 billion $1.15 billion down 6 percent

Celebrex Pain $634 million $591 million up 7 percent

Viagra Erectile dysfunction $496 million $470 million up 6 percent

Norvasc High blood pressure $334 million $356 million down 6 percent

Zyvox MRSA infections $325 million $319 million up 2 percent

Sutent Multiple cancers $300 million $276 million up 9 percent

Premarin/Prempro Menopause symptoms $261 million $235 million up 11 percent

___

Source: Pfizer Inc.

Rates

View Comments (0)